New drug combo aims to unleash immune system against melanoma
Disease control
Ongoing
This early-phase study tests a new drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can block cancer's ability to hide from the immune system, making the treatment more effective. About 77 participants will…
Phase: PHASE1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 17, 2026 01:26 UTC